Key result
Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization is an established therapy that requires further evidence to address remaining clinical uncertainties.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
A.M. Lincoff, E.J. Topol; Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?, European Hear
No takes yet. Share an insight, caveat, or question.
A. Michael Lincoff (2000) studied this question. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization is an established therapy that requires further evidence to address remaining clinical uncertainties.
Synapse has enriched 10 related papers. Consider them for comparative context: